Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial.

1066 Background: Ixabepilone (Ixa) is active in taxane-refractory metastatic breast cancer as well as in the neoadjuvant setting where Ixa yielded a pathologic complete response (pCR) rate of 18%. In this study, we evaluated Ixa in combination with cyclophosphamide (Cyc) as neoadjuvant treatment for HER2-negative breast cancer. The primary endpoint was pathologic complete response (pCR) rate, defined as no residual cancer in breast or lymph nodes. Responses were correlated with Oncotype DX recurrence scores. Methods: Eligible women were HER2-negative (IHC 0-1+ or FISH negative), node positive or T > 2 cm with inflammatory and T1N0 tumors excluded. Patients (pts) received Ixa 40mg/m2 with Cyc 600 mg/m2 day 1 of each 21-day cycle. Following 6 cycles, pts went to surgery. Postoperative radiation and hormonal treatments were at discretion of the treating MD. Core biopsies (pretreatment and at surgery) were analyzed using the Oncotype DX RT-PCR assay; the associations between recurrence scores and clinical res...